Scientists test 'Living Drug' to reset immune system in MS patients
NCT ID NCT07006805
Summary
This early-stage study is testing a new personalized therapy called CABA-201 for adults with multiple sclerosis (MS) that hasn't responded well to other treatments. Doctors will collect a patient's own immune cells, modify them in a lab to target the cells thought to drive MS, and then infuse them back. The main goals are to see if this approach is safe and to find the right dose, while also checking if it can reduce MS disease activity.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.